C12N 2710/16734
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16734 (Use of virus or viral component as vaccine) appears on 287 US grants and 293 published applications in this corpus.
Search patents in C12N- Granted patents
- 287
- Published applications
- 293
- Assignees
- 203
- Inventors
- 767
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 3 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 6 | 0 |
| 1988 | 3 | 0 |
| 1989 | 5 | 0 |
| 1990 | 0 | 0 |
| 1991 | 7 | 0 |
| 1992 | 5 | 0 |
| 1993 | 4 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 14 | 0 |
| 1998 | 15 | 0 |
| 1999 | 10 | 0 |
| 2000 | 7 | 0 |
| 2001 | 14 | 4 |
| 2002 | 6 | 7 |
| 2003 | 7 | 10 |
| 2004 | 7 | 8 |
| 2005 | 1 | 4 |
| 2006 | 4 | 4 |
| 2007 | 4 | 15 |
| 2008 | 2 | 9 |
| 2009 | 5 | 4 |
| 2010 | 4 | 9 |
| 2011 | 3 | 9 |
| 2012 | 1 | 6 |
| 2013 | 5 | 11 |
| 2014 | 7 | 17 |
| 2015 | 4 | 6 |
| 2016 | 7 | 21 |
| 2017 | 15 | 11 |
| 2018 | 12 | 15 |
| 2019 | 15 | 11 |
| 2020 | 8 | 13 |
| 2021 | 10 | 10 |
| 2022 | 12 | 22 |
| 2023 | 8 | 16 |
| 2024 | 6 | 17 |
| 2025 | 13 | 20 |
| 2026 | 7 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Varicella zoster virus (VZV) vaccine12 May 2026US 12,622,960 B2ModernaTX, Inc.
- Pharmaceutical composition and use thereof12 May 2026US 12,622,962 B2Grand Theravac Life Sciences (Nanjing) Co., Ltd.
- Shingles vaccines comprising a TLR9 agonist10 Mar 2026US 12,569,553 B2Dynavax Technologies Corporation
- Saponin purification17 Feb 2026US 12,552,831 B2Glaxosmithkline Biologicals SA
- Treatment regimen for the treatment of autoimmune disorders3 Feb 2026US 12,539,329 B2Merck Patent GmbH
- Mutated fragment of vzv glycoprotein e1 Oct 2026US 2026/0295035 A1
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- Fusion protein of ge and gi of varicella-zoster virus and use6 Aug 2026US 2026/0224694 A1
- Nucleic Acid Vaccines for Varicella-Zoster Virus (VZV)6 Aug 2026US 2026/0224695 A1Everest Medicines (Singapore) Pte. Ltd.
- Immunogenic compositions and methods of inducing an immune response against varicella zoster virus30 Jul 2026US 2026/0216319 A1Pfizer Inc.
Most cited
By later US patents
- Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence86US 5,223,424 APrutech Research And Development · 1993
- Attenuated, genetically-engineered pseudorabies virus S-PRV-155 and uses thereof79US 5,240,703 ASyntro Corporation · 1993
- Modified live BRSV vaccine77US 5,733,555 AAmerican Home Products Corporation · 1998
- Viral vectors and viral vaccines based on recombinant porcine adenoviruses75US 7,109,025 B1Ecole Nationale Veterinaire de Maison Alfort · 2006
- Varicella-zoster virus as a live recombinant vaccine69US 5,310,668 AMerck & Co., Inc. · 1994